BRPI0311233A2 - diagnóstico de carcinoma hepatocelular - Google Patents

diagnóstico de carcinoma hepatocelular

Info

Publication number
BRPI0311233A2
BRPI0311233A2 BRPI0311233A BRPI0311233A BRPI0311233A2 BR PI0311233 A2 BRPI0311233 A2 BR PI0311233A2 BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 A BRPI0311233 A BR PI0311233A BR PI0311233 A2 BRPI0311233 A2 BR PI0311233A2
Authority
BR
Brazil
Prior art keywords
diagnosis
hepatocellular carcinoma
hepatocellular
carcinoma
Prior art date
Application number
BRPI0311233A
Other languages
English (en)
Inventor
Jorge Filmus
Mariana Capurro
Original Assignee
Sunnybrook & Womens College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0311233(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunnybrook & Womens College filed Critical Sunnybrook & Womens College
Publication of BRPI0311233A2 publication Critical patent/BRPI0311233A2/pt
Publication of BRPI0311233B1 publication Critical patent/BRPI0311233B1/pt
Publication of BRPI0311233B8 publication Critical patent/BRPI0311233B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0311233A 2002-05-23 2003-05-22 métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra BRPI0311233B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38234002P 2002-05-23 2002-05-23
US60/382,340 2002-05-23
PCT/CA2003/000752 WO2003100429A2 (en) 2002-05-23 2003-05-22 Diagnosis of hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
BRPI0311233A2 true BRPI0311233A2 (pt) 2016-06-28
BRPI0311233B1 BRPI0311233B1 (pt) 2019-08-13
BRPI0311233B8 BRPI0311233B8 (pt) 2021-07-27

Family

ID=29584393

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311233A BRPI0311233B8 (pt) 2002-05-23 2003-05-22 métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra

Country Status (17)

Country Link
US (1) US7883853B2 (pt)
EP (1) EP1506406B1 (pt)
JP (1) JP4455324B2 (pt)
CN (1) CN100401068C (pt)
AT (1) ATE425461T1 (pt)
AU (1) AU2003229191B2 (pt)
BR (1) BRPI0311233B8 (pt)
CA (1) CA2482881C (pt)
DE (1) DE60326567D1 (pt)
ES (1) ES2324029T3 (pt)
IL (1) IL164848A0 (pt)
MX (1) MXPA04011132A (pt)
NZ (1) NZ536521A (pt)
PT (1) PT1506406E (pt)
RU (1) RU2319969C2 (pt)
WO (1) WO2003100429A2 (pt)
ZA (1) ZA200410077B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004022595A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
WO2004067571A1 (fr) * 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
EP1671645A4 (en) * 2003-09-04 2007-07-25 Chugai Pharmaceutical Co Ltd REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
WO2005085861A2 (en) * 2004-03-03 2005-09-15 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
JP4658926B2 (ja) 2004-04-28 2011-03-23 株式会社ペルセウスプロテオミクス 肝癌治療後の再発予測判定薬
CA2544692C (en) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR101300546B1 (ko) * 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
EP1813944A4 (en) * 2004-10-05 2009-11-11 Perseus Proteomics Inc DRUG TO MONITOR THE INJURY OF HEPATITIS
AU2005297772B2 (en) * 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053659A2 (en) * 2005-11-01 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of screening for hepatocellular carcinoma
KR20110005812A (ko) * 2008-03-17 2011-01-19 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법
CN101393217B (zh) * 2008-09-27 2012-05-30 中国人民解放军第二军医大学 一种原发性肝癌血清标志物的检测试剂盒
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
KR20100098324A (ko) * 2009-02-27 2010-09-06 포항공과대학교 산학협력단 Ｔｍ７ｓｆ３를 유효성분으로 함유하는 간암 진단용 조성물, 및 항 ｔｍ７ｓｆ３ 항체를 유효성분으로 함유하는 간암 진단 키트, 및 간암 예방 또는 치료용 약학 조성물
CN104634974B (zh) 2009-03-05 2017-08-08 独立行政法人产业技术综合研究所 肝内胆管癌的检出、辨别方法
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
CN102183660A (zh) * 2011-03-09 2011-09-14 倪温慨 检测Glypican-3的时间分辨免疫荧光试剂盒
CN102353791A (zh) * 2011-06-30 2012-02-15 倪润洲 一种分离检测afp亚型的新方法
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP4119947A1 (en) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
US20160000946A1 (en) * 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
WO2015020242A1 (ko) * 2013-08-06 2015-02-12 Kim Hyun Kee 소 간세포암 및 간경변에 잠재되어 있는 간세포암 진단용 조성물
CN105849562B (zh) 2013-12-24 2019-08-16 中外制药株式会社 可溶性gpc3蛋白质的测定方法
TWI735410B (zh) 2014-05-08 2021-08-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投予的ｇｐｃ３標的治療劑
EP3145952A2 (en) * 2014-05-22 2017-03-29 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101704533B1 (ko) * 2014-10-13 2017-02-09 경북대학교병원 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도
WO2017002934A1 (ja) 2015-07-01 2017-01-05 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US12168061B2 (en) * 2015-08-03 2024-12-17 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
EP3428648B1 (en) * 2016-03-10 2020-12-02 National Cancer Center Method for assisting prediction of recurrence risk in hepatocellular carcinoma patient, and use of a kit
US11767362B1 (en) 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
CN114813266B (zh) * 2022-03-15 2025-08-22 中国人民解放军海军军医大学第三附属医院 血液样本中gpc-3复合物的富集、检测方法及应用
WO2024255815A1 (zh) 2023-06-16 2024-12-19 信立泰(成都)生物技术有限公司 一种抗gpc3抗体或抗原结合片段及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU218175A (en) * 1974-09-12 1984-04-30 Schwartzhaupt Kg Process for total or individual determination of lactate dehydrogenase isoenzyme
US5171850A (en) * 1988-08-31 1992-12-15 The Ontario Cancer Institute Intestinal oncofetal gene
JP2946216B2 (ja) 1989-07-12 1999-09-06 武田薬品工業株式会社 新規ハイブリドーマ，モノクローナル抗体および用途
EP0477739A3 (en) * 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
AU769125B2 (en) * 1998-10-16 2004-01-15 Regents Of The University Of California, The Glypicans for the detection and treatment of human carcinoma
EP1411118B1 (en) * 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody

Also Published As

Publication number Publication date
HK1074251A1 (en) 2005-11-04
RU2004136285A (ru) 2005-10-10
DE60326567D1 (de) 2009-04-23
EP1506406B1 (en) 2009-03-11
BRPI0311233B8 (pt) 2021-07-27
IL164848A0 (en) 2005-12-18
JP4455324B2 (ja) 2010-04-21
ZA200410077B (en) 2005-12-28
PT1506406E (pt) 2009-06-03
US20050233392A1 (en) 2005-10-20
CA2482881A1 (en) 2003-12-04
EP1506406A2 (en) 2005-02-16
WO2003100429A2 (en) 2003-12-04
AU2003229191A1 (en) 2003-12-12
AU2003229191B2 (en) 2009-07-30
ES2324029T3 (es) 2009-07-29
US7883853B2 (en) 2011-02-08
CN1653336A (zh) 2005-08-10
WO2003100429A3 (en) 2004-02-19
CN100401068C (zh) 2008-07-09
CA2482881C (en) 2016-11-08
ATE425461T1 (de) 2009-03-15
MXPA04011132A (es) 2005-08-15
BRPI0311233B1 (pt) 2019-08-13
NZ536521A (en) 2006-04-28
JP2005526979A (ja) 2005-09-08
RU2319969C2 (ru) 2008-03-20

Similar Documents

Publication Publication Date Title
NO2026002I1 (no) Peginterferon beta-1a - forlenget
DE60316652D1 (de) Endoskop
EP1583997A4 (en) Photoresist DISTANCE
DE602004026245D1 (de) Endoskop
DE602004021746D1 (de) Endoskop
PL374898A1 (pl) Metoda ulepszonej diagnostyki dysplazji
DE602004001278D1 (de) Kochgerät
DE60304102D1 (de) Hautreinigungszusammensetzung
DE602004007867D1 (de) Kochgerät
EP1477118A4 (en) ULTRASOUND DEVICE
EP1665987A4 (en) ULTRASOUND DEVICE
DK1646311T3 (da) Endoskopisk fastgörelsesindretning
NO20045554L (no) Fremgangsmate for behandling av diabetes
FI5838U1 (fi) Kuori
DE60327130D1 (de) Entwicklungsgerät
EP1500370A4 (en) Ultrasonograph
DE50305758D1 (de) Mikroendoskop
DE60326190D1 (de) des Körpers
DE602004000627D1 (de) Hautreinigungsmittel
DE10347306B4 (de) Schirmanbindung
DE60321998D1 (de) Optometrisches Instrument
DE60303647D1 (de) Kochgerät
EP1683468A4 (en) Endoscope
DE60317022D1 (de) Biosensor
DE60314798D1 (de) Entwicklungsgerät

Legal Events

Date Code Title Description
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/05/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.